Cardarine (GW501516) Research Guide

What Is Cardarine (GW501516)?

Cardarine (GW501516, GW1516) is a PPARδ agonist developed in the late 1990s by GlaxoSmithKline (GSK) and Ligand Pharmaceuticals as part of a collaborative metabolic disease drug discovery program. Despite being grouped with SARMs in research chemical markets, it is mechanistically completely different — it does not bind the androgen receptor.

PPARδ (peroxisome proliferator-activated receptor delta, also called PPARβ/δ) is a nuclear receptor that regulates fatty acid oxidation, glucose metabolism, and mitochondrial function — particularly in skeletal muscle, heart, and adipose tissue. GW501516 is one of the most potent and selective PPARδ agonists available as a research tool.

PPARδ Biology

PPARδ is expressed highly in skeletal muscle, heart, and adipose tissue, where it regulates a broad gene program:

• Fatty acid oxidation genes: CPT1A/B (carnitine palmitoyltransferase, rate-limiting step in mitochondrial fat import), HADHA, ACADM — increasing capacity for fat as fuel
• Slow-twitch fiber genes: MyHC IIa (fast-to-slow fiber type shift), troponin I slow — explained by the "slow-twitch transformation" observed in muscle after chronic PPARδ activation
• Mitochondrial biogenesis: Indirect upregulation via PGC-1α coactivation
• Anti-inflammatory: PPARδ activation suppresses NF-κB and macrophage-derived inflammatory cytokines — relevant for atherosclerosis research

Fat Oxidation & Metabolic Research

GSK's internal research and published Phase I/IIa data showed:

• Dyslipidemia Phase IIa: GW501516 10 mg/day for 12 weeks in subjects with metabolic syndrome: LDL cholesterol reduced by ~17%; HDL cholesterol increased by ~6%; triglycerides reduced; insulin sensitivity improved.
• Fatty liver: Reduction in liver fat and liver enzymes in rodent models of non-alcoholic fatty liver disease (NAFLD)
• Adipose tissue: Reduced fat mass and increased fat oxidation rate (measured by indirect calorimetry) in rodent models

Endurance Research: Narkar et al. (2008)

The Narkar et al. study (Cell, 2008, Salk Institute) is one of the most widely cited exercise biology papers and the primary reference for GW501516 as an "exercise mimetic":

• Key finding: Mice treated with GW501516 alone showed a 44% increase in treadmill running distance vs controls. Mice treated with GW501516 + AICAR (AMPK agonist) ran 77% longer — a synergistic effect greater than either alone.
• Mechanism: GW501516 alone did not increase mitochondrial content significantly — its endurance effect appeared to be primarily through fatty acid oxidation gene expression, allowing greater fat utilization during exercise
• Fiber type shift: Chronic GW501516 treatment increased the proportion of slow-twitch (type I and IIa) fibers in mouse skeletal muscle

Carcinogenicity: Why GSK Halted Development

This section is critical for any researcher designing in vivo protocols using GW501516:

GSK conducted standard 2-year rodent carcinogenicity studies (required for any drug seeking marketing authorization). Results (Peraza et al., 2008):

• Dose-dependent tumor formation in multiple tissue types (liver, stomach, tongue, skin, bladder, urinary tract) at doses of 5, 15, and 30 mg/kg for 104 weeks
• Multiple tissue sites: The breadth of tumor types suggested a general proliferative/pro-carcinogenic effect rather than tissue-specific carcinogenesis
• Mechanism hypothesis: PPARδ activation promotes cell survival and proliferation (anti-apoptotic effects) — beneficial for metabolic research but potentially enabling tumor cell growth

Research implications: Short-term in vitro studies and acute/subacute rodent models are not subject to the same carcinogenicity concerns as 2-year chronic studies. However, institutional biosafety review is required for any in vivo protocol. Researchers should consult their IACUC and institutional guidelines before including GW501516 in animal study designs.

Cardarine vs SLU-PP-332 vs AICAR

For exercise mimetic research without carcinogenicity considerations, SLU-PP-332 and AICAR are alternatives that target overlapping but distinct nodes of the metabolic adaptation pathway.